Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Infection ; 50(4): 1007-1012, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1756953

ABSTRACT

BACKGROUND: Cryptococcal infection has been increasingly reported in patients with COVID-19 infection, but the epidemiological factors, presentation, diagnostic certainty, and outcome have not been well-described. METHODS: We reviewed the published cases of COVID-19-associated Cryptococcus infections (CACI) to shed the light on the burden of this infection. RESULTS: We identified 13 patients with confirmed cryptococcal infection. Cryptococcus infection was primarily seen in patients with severe COVID-19 disease who received corticosteroids therapy and admitted to the intensive care unit. Pulmonary CACI was the most common reported infection followed by cryptococcal meningitis. CONCLUSION: In light of the high mortality rate, clinicians should maintain a high clinical suspicion of CACI in critically ill patients.


Subject(s)
COVID-19 , Cryptococcosis , Cryptococcus , Meningitis, Cryptococcal , Cryptococcosis/complications , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Humans , Meningitis, Cryptococcal/drug therapy
3.
Pathogens ; 10(3)2021 Mar 22.
Article in English | MEDLINE | ID: covidwho-1154466

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented threat to the international community and raised major concerns in terms of public health safety. Although our current understanding of the complexity of COVID-19 pathogenesis remains limited, the infection is largely mediated by the interaction of viral spike protein and angiotensin-converting enzyme 2 (ACE2). The functional importance of ACE2 in different demographic and comorbid conditions may explain the significant variation in incidence and mortality of COVID-19 in vulnerable groups, and highlights its candidacy as a potential therapeutic target. We provide evidence supporting the idea that differences in incidence and severity of COVID-19 infection may be related to ACE2. Emerging data based on the prevalence and severity of COVID-19 among those with established high levels of ACE2 expression strongly support our hypothesis. Considering the burden of COVID-19 infection in these vulnerable groups and the impact of the potential therapeutic and preventive measures that would result from adopting ACE2-driven anti-viral strategies, our hypothesis may expedite global efforts to control the current COVID-19 pandemic.

4.
Transpl Infect Dis ; 23(4): e13606, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1146666

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.


Subject(s)
COVID-19 , Hematopoietic Stem Cell Transplantation , Immune Reconstitution , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , SARS-CoV-2 , Transplant Recipients
6.
Br J Cancer ; 124(7): 1183, 2021 03.
Article in English | MEDLINE | ID: covidwho-1007651

ABSTRACT

The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting in cytokine storm, respiratory failure and severe outcomes.


Subject(s)
COVID-19/epidemiology , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , COVID-19/complications , COVID-19/virology , Cytokine Release Syndrome/chemically induced , Granulocyte Colony-Stimulating Factor/adverse effects , Hematologic Neoplasms/complications , Humans , Prognosis , Respiratory Insufficiency/chemically induced , SARS-CoV-2/isolation & purification
7.
Mediterr J Hematol Infect Dis ; 12(1): e2020044, 2020.
Article in English | MEDLINE | ID: covidwho-854283

ABSTRACT

The emergence and spread of 2019 novel coronavirus have led to an unprecedented public health crisis around the globe, threatening the lives of millions of people. We report a severe case of COVID-19 in a patient with chronic lymphocytic leukemia and describe primarily the clinical presentation and the challenges encountered in the COVID-19 diagnosis, treatment, and specimens sampling pitfalls. This case highlights the importance of a comprehensive diagnostic approach of pneumonia in immunocompromised hosts, including timely and safe bronchoscopy, because of the broad differential diagnosis, more challenging with the current outbreak of COVID-19.

8.
Lancet ; 396(10257): 1066-1067, 2020 10 10.
Article in English | MEDLINE | ID: covidwho-845035
10.
IDCases ; 21: e00864, 2020.
Article in English | MEDLINE | ID: covidwho-548692

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

SELECTION OF CITATIONS
SEARCH DETAIL